Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites, and heart failure, today announces that it has completed implanting patients in POSEIDON, the North American pivotal study to support regulatory approval of the alfapump system in the U.S. and Canada, for the treatment of recurrent or refractory ascites due to liver cirrhosis.

Sonendo, Inc. (“Sonendo”), a leading dental technology company and developer of the GentleWave® System, today reported financial results for the quarter and year ended December 31, 2021.

Sonendo, Inc. (NYSE: SONX), a dental technology company and creator of the GentleWave System for less invasive and less painful root canal therapy, today announced its achievement of a new milestone of 800,000 GentleWave patient procedures. The achievement of this newest milestone demonstrates the confidence doctors and their patients have in the GentleWave System as an alternative to traditional root canal therapy, and the growing utilization and preference among customers for the GentleWave procedure. The milestone follows on the heels of the Company’s achievement of its 700,000 procedures milestone in late 2021.

Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, announces that in the context of the capital increase that was announced on 7 March 2022 and completed on 10 March 2022 by means of a private placement through an accelerated bookbuilding procedure, its share capital has increased from EUR 1,925,158.02 to EUR 2,460,486.98 and the number of issued and outstanding shares has increased from 18,579,260 to 23,746,528 ordinary shares, through the issuance of a total of 5,167,268 new shares.